Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review

INTRODUCTION: The prognosis for recurrent intrahepatic cholangiocarcinoma with bone metastasis remains dismal and its treatment poses a challenge for oncologists. To date, only 2 cases were reported in which pembrolizumab, an agent against programmed cell death protein-1 (PD-1), combined with chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei-xun, Li, Gan-xun, Hu, Zheng-nan, Zhu, Peng, Zhang, Bi-xiang, Ding, Ze-yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855517/
https://www.ncbi.nlm.nih.gov/pubmed/31702638
http://dx.doi.org/10.1097/MD.0000000000017832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855517/
https://www.ncbi.nlm.nih.gov/pubmed/31702638
http://dx.doi.org/10.1097/MD.0000000000017832

Ejemplares similares